medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2017, Number 4

<< Back Next >>

Acta Ortop Mex 2017; 31 (4)

A comparative study in patients with fractures of the lower limbs between rivaroxaban versus enoxaparin and its impact on bone healing time

Peláez-Damy P, Torres-Gómez A, Mas-Celis F, Martínez-Villalobos M

Language: English
References: 21
Page: 177-181
PDF size: 134.23 Kb.


ABSTRACT

Background: Each year it is estimated in the United States an approximate of 8 million fractures; 5 to 10% develop delayed union or absence of periosteal new bone. There are several factors that can cause delay in fracture healing, among the well known, is the use of prophylactic antithrombotic therapy for deep vein thrombosis (DVT). DVT appears in 40 to 60% of the patients undergoing orthopedic surgery without prophylactic antithrombotic therapy. The goal of this study was to assess whether there is a difference in time of bone healing in lower limb fractures (femur and tibia) comparing rivaroxaban to enoxaparin as the prophylactic antithrombotic management. Material and methods: We present a retrospective observational and analytic study in a sample of cases. It is a cross-sectional study with patient data from the database of the American British Cowdray (ABC) Medical Center. We included patients with femur and tibia fractures under antithrombotic prophylactic management with rivaroxaban or enoxaparin during the period of January 2011 to December 2012. Our sample included 32 patients separated into two groups. Student’s t-test was used for comparing parametric variables and the Mann-Whitney U test for nonparametric variables. Linear regression model was preformed considering the variables related to the time it took the fracture to heal. Results: All fractures consolidated in a time of 13 and 14 weeks for rivaroxaban and enoxaparin respectively (p = 0.67). Discussion: We found no difference in bone healing time for lower limb fractures in patients receiving antithrombotic prophylaxis treatment comparing rivaroxaban with enoxaparin.


REFERENCES

  1. Nelson FR, Brighton CT, Ryaby J, Simon BJ, Nielson JH, Lorich DG, et al. Utilización de fuerzas físicas en la consolidación ósea. J Am Acad Orthop Surg (Ed Esp). 2003; 2(6): 388-98.

  2. Colchero RF: La consolidación de las fracturas, su fisiología y otros datos clínicos de importancia. Revista Médica IMSS. 1982; 21(4): 374-81.

  3. Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ: Trends in fracture incidence: a population-bases study over 20 years. J Bone Miner Res. 2014; 29(3): 581-9.

  4. Martínez A. Factores clínicos que modifican la consolidación de fracturas. Avances en Traumatología, Cirugía Ortopédica y Rehabilitación. 2005; 33(3): 153-62.

  5. Pretell MJ, Ruiz SC, Rodríguez MJ: Trastornos de la consolidación: retardo y pseudoartrosis. Rev Med Hered. 2009; 20(1): 31-9.

  6. Babhulkar S, Pande K, Babhulkar S: Nonunion of the diaphysis of long bones. Clin Orthop Relat Res. 2005; (431): 50-6.

  7. Delgado MA, Alcántara MT: Agentes sistémicos que modifican la consolidación de las fracturas. Rev Esp Ortop Traumatol. 2006; 50(1): 5-12.

  8. Giannoudis PV, McDonald DA, Matthws SJ, Smith RM, Furlong AJ, De Boer P: Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg. 2000; 82(5): 655-8.

  9. Lee J, Patel R, Biermann JS, Doughetry P: The musculoskeletal effects of cigarette smoking. J Bone Joint Surg Am. 2013; 95(9): 850-9.

  10. Street JT, McGrath M, O’Regan K, Wakai A, McGuinness A, Redmond HP: Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res. 2000; (381): 278-89.

  11. Seung YL, Du HR, Chin YC, Kyoung ML, Soon-Sun K, Moon SP: Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J. 2015; 56(1): 139-45.

  12. Turpie AG: Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg. 1991; 161(4): 532-6.

  13. Lazo LA, Fleet JL, Mcarthur E, Gard AX: Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. J Thromb Haemost. 2014; 12(10): 1626-35.

  14. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG: The effects of heparin and low molecular weight heparins on bone. Thromb Res. 2008; 122(3): 293-8.

  15. European Commission approval for Xarelto. European Medicines Agency. Evaluation of Medicines for Human Use. 2008. (Doc.Ref: EMEA/543519/2008)

  16. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, et al: Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009; 91(5): 636-44.

  17. Walenga JM, Bick RL: Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am. 1998; 82(3): 635-58.

  18. Gigi R, Salai M, Dolkart O, Chechik O, Katzburg S, Stern N, Somjen D: The effects of direct factor Xa inhibitor (rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res. 2012; 53(6): 446-50.

  19. Somjen D, Katzburg S, Gigi R, Dolkart O, Sharon O, Salai M, et al: Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human females osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013; (135): 67-70.

  20. Solayar GN, Walsh PM, Mulhall KJ: The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskeletal Disordr. 2011; 12: 247

  21. Reyna G, Soto I, Regalado R: Aplicación de medulla ósea autologa en retardos de consolidación y seudoartrosis postraumática. Acta Ortopédica Mexicana. 2005; 19(6): 248-51.




2020     |     www.medigraphic.com